Phase 3 trial results presented at ASN Kidney Week 2026 show that atacicept, sibeprenlimab and telitacicept provided kidney ...

Final data from ORIGIN and VISIONARY trials pave way for full FDA approvals ...

Kidney Week 2026 brought strong IgAN data, looked back on 5 years of value-based kidney care, and highlighted evidence of ...

Significant proteinuria reductions reported, but still awaiting eGFR data ...

ROCKVILLE, Md., July 20, 2026 (GLOBE NEWSWIRE)-- Today, the American Kidney Fund (AKF) and the IgA Nephrology Foundation announce the creation of a new resource for IgA nephropathy patients and their ...

FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic ...

After an IgA nephropathy (IgAN) diagnosis, your care team has likely discussed different treatment options with you, including some newer targeted therapies such as targeted-release budesonide or ...

Treatment with telitacicept significantly reduced proteinuria in patients with immunoglobulin A (IgA) nephropathy compared with placebo, according to data from a phase 3 study involving more than 300 ...

VIENNA — Sibeprenlimab, a novel selective immune antibody, reduced the urine protein-to-creatinine ratio (uPCR) by more than half in patients with immunoglobulin A (IgA) nephropathy, according to an ...

Learn why Oxford scores predict IgA nephropathy outcomes, and how supportive drugs plus low-salt lifestyle protect remaining nephrons. What makes this approach more selective or safer from a ...

ROCKVILLE, Md., July 20, 2026 (GLOBE NEWSWIRE)-- Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation announce the creation of a new resource for IgA nephropathy patients and their ...